The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Disease‐modifying strategies for Parkinson's disease
Abstract
Parkinson's disease (PD) is an increasingly prevalent and progressively disabling neurodegenerative disease. The impact of PD on patients and their families as well as its burden on health care systems could be substantially reduced by disease‐modifying therapies that slow the rate of neurodegeneration or stop the disease process. Multiple agents have been studied in clinical trials designed to assess disease modification in PD, but all have failed. Over the last 3 years, clinical trials investigating the potential of adeno‐associated virus serotype 2 (AAV)‐neuturin, coenzyme Q10, creatine, pramipexole, and pioglitazone reported negative findings or futility. Despite these disappointments, progress has been made by expanding our understanding of molecular pathways involved in PD to reveal new targets, and by developing novel animal models of PD for preclinical studies. Currently, at least eight ongoing clinical trials are testing the promise of isradipine, caffeine, nicotine, glutathione, AAV2‐glial cell‐line derived neurotrophic factor (GDNF), as well as active and passive immunization against α‐synuclein (α‐Syn). In this review, we summarize the clinical trials of disease‐modifying therapies for PD that were published since 2013 as well as clinical trials currently in progress. We also discuss promising approaches and ongoing challenges in this area of PD research. © 2015 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
The prion hypothesis in Parkinson's disease: braak to the future
Visanji, N. P., Brooks, P. L., Hazrati, L.-N., & Lang, A. E. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-2 · Cited by 278
Self-citationBioenergetic approaches for neuroprotection in Parkinson's disease
Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy
Schapansky, J., Nardozzi, J. D., Felizia, F., & LaVoie, M. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu138 · Cited by 226
Chotibut, T., Davis, R. W., Arnold, J. C., Frenchek, Z., Gurwara, S., Bondada, V., Geddes, J. W., & Salvatore, M. F. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8598-0 · Cited by 86
Ho, S.-C., Hsu, C.-C., Pawlak, C. R., Tikhonova, M. A., Lai, T.-J., Amstislavskaya, T. G., & Ho, Y.-J. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.04.022 · Cited by 65 · cited 1×
“For instance, the commonly used cephalosporin antibiotic ceftriaxone has been found to bind to a-Syn and block its in vitro aggregation,(55) as well as to reduce dopaminergic neuron loss in MPTP and 6-OHDA rodent models.(56,57) A meta-analysis using data from prior clinical drug trials for early PD found that tricycli…”
Background
Cited by
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology
Simon, D. K., Tanner, C. M., & Brundin, P. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.08.002 · Cited by 1,114
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“lnflammation is a major component of PD pathogenesis, and a clinical trial using Pioglitazone, a peroxisome proliferator-activated receptor-g agonist that reduces proinflammatory cytokines and modulates mitochondrial biogenesis, was performed.(70,273) However, this trial failed to meet its primary endpoint as well.”
Self-citationMagrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016) · Parkinson's Disease · doi:10.1155/2016/9832839 · Cited by 369
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
A Review of Low-Intensity Pulsed Ultrasound for Therapeutic Applications
Jiang, X., Savchenko, O., Li, Y., Qi, S., Yang, T., Zhang, W., & Chen, J. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2018.2889669 · Cited by 353
Metadata
- Authors
- Kalia, L. V., Kalia, S. K., & Lang, A. E.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2015-07-24
- Volume
- 30
- Issue
- 11
- Pages
- 1442-1450
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1626583747
- Cited by
- 251
- References
- 8
- FWCI
- 17.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disease‐modifying strategies for Parkinson's disease. https://app.cochat.ai/papers/10.1002/mds.26354
- The paper
- Kalia, L. V., Kalia, S. K., & Lang, A. E. (2015). Disease‐modifying strategies for Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.26354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
